Company Description

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States.

It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.

The company’s product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases.

The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam’s proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells.

The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes.

The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018.

Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.